Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Supportive Care in Cancer
Erschienen in: Supportive Care in Cancer 5/2013

01.05.2013 | Original Article

Development of anxiety and depression in patients with benign intracranial meningiomas: a prospective long-term study

verfasst von: Simone Goebel, H. Maximilian Mehdorn

Erschienen in: Supportive Care in Cancer | Ausgabe 5/2013

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The aim of this study was to provide the first prospective longitudinal assessment of anxiety and depression in patients with a benign intracranial meningioma (WHO° I).

Methods

The Hospital Anxiety and Depression Scale was applied prior to (t1) and directly after (t2) neurosurgery as well as 6 months after surgery (t3). The research was conducted in a single treatment centre in Germany. Numerous sociodemographic, medical, psychological and cognitive accompanying measures were assessed. The study population consisted of 52 meningioma patients. Additionally, a control group of 24 patients with malignant brain tumours (astrocytoma WHO° III) was assessed.

Results

In meningioma patients, anxiety was high prior to surgery but declined significantly after successful neurosurgical treatment. Low levels of depression were observed at all times. In contrast, astrocytoma patients showed constantly high levels of anxiety whilst depression increased over the course of the disease. Numerous medical, psychosocial and psychological factors were associated with psychiatric morbidity in meningioma patients.

Conclusions

In conclusion, psychiatric morbidity of patients with benign intracranial meningiomas was comparable to that of the general population after successful neurosurgical treatment. Numerous associated factors suggest complex relationships within a biopsychosocial model. However, due to the small sample size and recruitment in a single institution, our results are of limited generalisability and need cross-validation in future studies.
Literatur
1.
Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97–109PubMedCrossRef
2.
Kleihues P, Burger PC, Scheithauer BW (1993) Histological typing of tumours of the central nervous system: international histological classification of tumours, 2nd edn. Springer, BerlinCrossRef
3.
Lee JH (2009) Meningiomas: diagnosis, treatment, and outcome, 1st edn. Springer, London
4.
Pace A, Di Lorenzo C, Lorenzo CD, Guariglia L, Jandolo B, Carapella CM, Pompili A (2009) End of life issues in brain tumor patients. J Neuro-Oncol 91(1):39–43CrossRef
5.
Pringle A-A, Taylor R, Whittle IR (1999) Anxiety and depression in patients with an intracranial neoplasm before and after tumour surgery. Br J Neurosurg 13:46–51PubMedCrossRef
6.
7.
Zabora JR, BrintzenhofeSzoc KM, Curbow B, Hooker C, Piantadosi S (2001) The prevalence of psychological distress by cancer site. Psycho-Oncol 10:19–28CrossRef
8.
Goebel S, Stark A, Kaup L, von Harscher M, Mehdorn HM (2011) Distress in patients with newly diagnosed brain tumours. Psycho Oncol 20(6):623–630CrossRef
9.
Giovagnoli AR, Boiardi A (1994) Cognitive impairment and quality of life in long-term survivors of malignant brain tumors. Ital J Neurol Sci 15(9):481–488PubMedCrossRef
10.
Tsay SL, Chang JY, Yates P, Lin KC, Liang SY (2012) Factors influencing quality of life in patients with benign primary brain tumors: prior to and following surgery. Support Care Cancer 20:57–64PubMedCrossRef
11.
Arnold SD, Forman LM, Brigidi BD, Carter KE, Schweitzer HA, Qiunn HE, Bebe Guill A, Herndon JE, Raynor RH (2008) Evaluation and characterization of generalized anxiety and depression in patients with primary brain tumors. J Neuro-Oncol 10:171–181CrossRef
12.
Goebel S, Strenge H, Mehdorn HM (2011) Acute stress in patients with brain cancer during primary care. Support Care Cancer 20(7):1425–1434
13.
Pace A, Metro G, Fabi A (2010) Supportive care in neurooncology. Curr Opin Oncol 22(6):621–626PubMedCrossRef
14.
Rooney AG, Carson A, Grant R (2011) Depression in cerebral glioma patients: a systematic review of observational studies. J Natl Cancer Inst 103(1):61–76PubMedCrossRef
15.
D'Angelo C, Mirijello A, Leggio L, Ferrulli A, Carotenuto V, Icolaro N, Miceli A, D'Angelo V, Gasbarrini G, Addolorato G (2008) State and trait anxiety and depression in patients with primary brain tumors before and after surgery: 1-year longitudinal study. J Neurosurg 108(2):281–286PubMedCrossRef
16.
Litofsky NS, Farace E, Anderson F, Meyers CA, Huang W, LE R (2004) Depression in patients with high-grade glioma: results of the glioma outcome project. Neurosurgery 54:358–366PubMedCrossRef
17.
Mainio A, Hakko H, Niemela A, Koivukangas J, Rasanen P (2005) Depression and functional outcome in patients with brain tumours: a population based 1-year follow-up study. J Neurosurg 103:841–847PubMedCrossRef
18.
Zigmond AS, Snaith RP (1983) The hospital anxiety and depression scale. Acta Psychiatr Scand 67:361–370PubMedCrossRef
19.
Bjelland I, Dahl AA, Haug TT, Neckelmann D (2002) The validity of the Hospital Anxiety and Depression Scale—an updated literature review. J Psychosom Res 52:69–77PubMedCrossRef
20.
Karnofsky DA, Burchenal JH (1949) The clinical evaluation of chemotherapeutic agents in cancer. In: MacLeod CM (ed) Evaluation of chemotherapeutic agents. Columbia Universitiy Press, New York, pp 191–205
21.
Krannich JH, Weyers P, Lueger S, Herzog M, Bohrer T, Elert O (2007) Presence of depression and anxiety before and after coronary artery bypass graft surgery and their relationship to age. BMC Psychiatry 7:47PubMedCrossRef
22.
Hinz A, Zweynert U, Kittel J, Igl W, Schwarz R (2009) Measurement of change with the Hospital Anxiety and Depression Scale (HADS): sensitivity and reliability of change. Psychother Psychosom Med Psychol 59:394–400PubMedCrossRef
23.
Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85(5):365–376PubMedCrossRef
24.
Schumacher J, Klaiberg A, Brähler E (2003) Diagnostische Verfahren zu Lebensqualität und Wohlbefinden. Hogrefe, Göttingen
25.
Foa EB (1997) Posttraumatic Stress Diagnostic Scale (PDS®). Pearson, San Antonio
26.
Fydrich T, Sommer G, Brähler E (2007) F-SozU-Fragebogen zur Sozialen Unterstützung. Hogrefe, Göttingen
27.
Lezak MD, Howieson DB, Loring DW (2004) Neuropsychological assessment, 4th edn. Oxford University Press, New York
28.
Warrington EK, James M (1992) Testbatterie für visuelle Objekt-und Raumwahrnehmung (VOSP). Thames Valley Test Company, Bury St Edmunds
29.
Wechsler D (1987) Wechsler Memory Scale-Revised. The Psychological Corporation, San Antonio
30.
Benton AL, Kd H (1989) Multilingual aphasia examination. AJA Associates, Iowa City
31.
Huber W, Poeck K, Weninger D, Willmes K (1983) Der Aachener Aphasie Test (AAT). Hogrefe, Göttingen
32.
Leonhart R (2004) Effektgrößenberechnung bei Interventionsstudien. Die Rehabil 43:241–246CrossRef
33.
Leplow B, Friege L (1998) Eine Sozialformel zur Schätzung der prämorbiden Intelligenz. Z Klin Psychol 27:1–8
34.
Hinz A, Krauss O, Hauss JP, Höckel M, Kortmann RD, Stolzenburg JU, Schwarz R (2009) Anxiety and depression in cancer patients compared with the general population. Eur J Cancer Care 19:522–529CrossRef
35.
Mainio A, Hakko H, Timonen M, Niemelä A, Koivukangas J, Räsänen P (2005) Depression in relation to survival among neurosurgical patients with primary brain tumor: a 5-year follow-up study. Neurosurgery 56:1234–1242PubMedCrossRef
36.
Ownsworth T, Hawkes A, Steginga S, Walker D, Shum D (2009) A biopsychosocial perspective on adjustment and quality of life following brain tumor: a systematic evaluation of the literature. Disabil Rehabil 31:1038–1055PubMedCrossRef
37.
Kilbride L, Smith G, Grant R (2007) The frequency and cause of anxiety and depression amongst patients with malignant brain tumours between surgery and radiotherapy. J Neuro Oncol 84(3):297–304CrossRef
38.
Goebel S, Kaup L, Mehdorn HM (2011) Measuring preoperative anxiety in patients with intracranial tumours: the Amsterdam Preoperative Anxiety and Information Scale (APAIS). J Neurosurg Anesthesiol 23(4):297–303PubMedCrossRef
39.
Gupta DK, Chandra PS, Ojha BK, Sharma BS, Mahapatra AK, Mehta VS (2007) Awake craniotomy versus surgery under general anesthesia for resection of intrinsic lesions of eloquent cortex—a prospective randomised study. Clin Neurol Neurosurg 109:335–343PubMedCrossRef
40.
Janda M, Steginga S, Langbecker D, Dunn J, Walker D, Eakin E (2007) Quality of life among patients with a brain tumour and their carers. J Psychosom Res 63:617–623PubMedCrossRef
41.
Armstrong C, Goldstein B, Cohen B, Jo M, Tallent E (2002) Clinical predictors of depression in patients with low-grade brain tumors: consideration of a neurologic versus a psychogenic model. J Clin Psychol Med Settings 9(2):97–107CrossRef
42.
Wellisch DK, Kaleita TA, Freeman D, Cloughesy T, Goldman J (2002) Predicting major depression in brain tumor patients. Psycho-Oncology 11:230–238PubMedCrossRef
43.
Salander P, Bergenheim T, Henriksson R (1996) The creation of protection and hope in patients with malignant brain tumours. Soc Sci Med 42(7):985–996PubMedCrossRef
44.
Pelletier G, Verhoef MJ, Khatri N, Hagen N (2002) Quality of life in brain tumor patients: the relative contributions of depression, fatigue, emotional distress, and existential issues. J Neuro Oncol 57:41–49CrossRef
45.
Molassiotis A, Wilson B, Brunton L, Chaudhary H, Gattamaneni R, McBain C (2010) Symptom experience in patients with primary brain tumours: a longitudinal exploratory study. Eur J Oncol Nurs 14:410–416PubMedCrossRef
Metadaten
Titel
Development of anxiety and depression in patients with benign intracranial meningiomas: a prospective long-term study
verfasst von
Simone Goebel
H. Maximilian Mehdorn
Publikationsdatum
01.05.2013
Verlag
Springer-Verlag
Erschienen in
Supportive Care in Cancer / Ausgabe 5/2013
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-012-1675-5

Weitere Artikel der Ausgabe 5/2013

Supportive Care in Cancer 5/2013 Zur Ausgabe

Original Article

The minimal clinical important difference in the World Health Organization Quality of Life instrument—100

Original Article

Developing a national ‘low risk’ febrile neutropenia framework for use in children and young people's cancer care

Original Article

Efficacy of oral palonosetron compared to intravenous palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: a phase 3 trial

Original Article

Advance care planning among Colombian, Mexican, and Puerto Rican women with a cancer diagnosis

Review Article

Thromboembolic disease in cancer patients

Original Article

Treatment of acute and chronic focal neuropathic pain in cancer patients with lidocaine 5 % patches. A radiation and oncology department experience

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

23.04.2024 Medikamente in Schwangerschaft und Stillzeit Nachrichten

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise